Breaks Categories: Stock Spotlights

FridayJun 29, 2018 12:25 pm

CannabisNewsBreaks – Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) Actively Targets Cannabis Market in California

Vertically integrated cannabis company Sunniva’s (CSE: SNN) (OTCQX: SNNVF) core subsidiaries and licensed tenant cultivators are gearing up to supply the multibillion dollar recreational and medical cannabis industries in California. A recent article discussing the company’s unique technology reads: “Sunniva CEO Dr. Anthony Holler notes that the company has received all temporary state licenses required in California. Sunniva’s U.S. subsidiaries hold eight 10,000 square foot cultivation licenses, two manufacturing licenses, one 22,000 square foot cultivation license, one 22,000 square foot nursery license and one 10,000 square foot nursery license. Another seven 22,000 square foot cultivation bays will be leased to…

Continue Reading

ThursdayJun 28, 2018 2:52 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Continues to Build Patent Portfolio

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is in the process of preparing new patent application filings and expects to receive more patent awards this year to add to its collection of over 40 patent awards or applications from 40 countries globally. A recent article discussing the company reads: “The total, once granted, would be four patents in the U.S. and four in Australia. All eight are for the family of “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” The development represents the first time that LXRP has expanded its patent protection outside of…

Continue Reading

ThursdayJun 28, 2018 11:48 am

CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Develops Innovative Therapies as Alternative Medicine Market Surges

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is developing pioneering options for preventive and curative therapies by utilizing several creative pathways. An article further discussing the company reads: “Chronic diseases and recurring health care issues are taking an increasingly bigger piece of the economic pie and disrupting the lives of many millions of people. U.S. health care costs for chronic diseases totaled $1.1 trillion in 2016 and balloon to $3.7 trillion when lost economic productivity is calculated into the total economic impact. According to a new report by Grand View Research, people around the world, along with their…

Continue Reading

ThursdayJun 28, 2018 11:39 am

CannabisNewsBreaks – Why Koios Beverage Corp. (CSE: KBEV) is “One to Watch”

Koios Beverage (CSE: KBEV) develops and distributes nature-based products such as nootropics, which are supplements that improve cognitive abilities. An article further discussing the company reads: “Not to be mistaken with prescription-only drugs which are at times used for similar effects, nootropics are over-the-counter dietary supplements; some of which, like Koios, contain ingredients that are currently used in the treatment of patients with Alzheimer’s disease. The global field of nootropics is growing rapidly and expected to reach USD $6,059.4 Mn by 2024 with a CAGR of 17.9 percent from 2016 to 2024. … According to media reports, there is believed…

Continue Reading

WednesdayJun 27, 2018 2:32 pm

CannabisNewsBreaks – Why FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is “One to Watch”

FinCanna Capital (CSE: CALI) (OTCQB: FNNZF), a royalty company for the U.S. licensed medical cannabis industry, operates an attractive royalty model that is beneficial for operators and the company. An article further discussing the company reads: “FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to…

Continue Reading

MondayJun 25, 2018 12:21 pm

CannabisNewsBreaks – BLOCKStrain Technology Corp. (TSX.V: DNAX) Advances Company Know-how with New Advisory Board Member

BLOCKStrain Technology (TSX.V: DNAX) recently announced that it has added Derek Pedro to its advisory board, furthering the company’s expertise as it develops its software platform for licensed producers and industry stakeholders. An article discussing the company reads: “BLOCKStrain Technology Corp. (TSX.V: DNAX) has named Derek Pedro, an industry veteran of the legalized cannabis industry in Canada, to its advisory board. For joining the advisory board, Pedro will receive 500,000 stock options.  A master grower, Pedro is particularly interested in protection of the IP of cannabis producers, as well as governmental tracking of cannabis shipments worldwide. These are issues that…

Continue Reading

FridayJun 22, 2018 11:32 am

CannabisNewsBreaks – BLOCKStrain Technology Corp. (TSX.V: DNAX) Develops Safe, Dependable Blockchain Platform

BLOCKStrain Technology (TSX.V: DNAX) has developed a blockchain platform that can be trusted to provide both safety and reliability. An article discussing the company reads: “The BLOCKStrain platform aims to provide the integrity that the current system so sorely lacks. It goes further by ensuring product authenticity and IP protection, with a genetics verification process. Producers and marketers can take advantage of this novel methodology by submitting the lab results of tested samples to BLOCKStrain. Each time an item is tested and verified by the network, a registration affidavit is auto-generated and given a unique “BLOCKStrain Address,” along with a…

Continue Reading

ThursdayJun 21, 2018 3:04 pm

CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Takes Aim at Massive Alternative Medicines Market

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is pursuing therapies for a variety of physical ailments through nature-centric research. An article discussing the company reads: “PreveCeutical’s drive to develop its Nature Identical line of biopharmaceuticals positions it to take advantage of the mainstreaming of the complementary and alternative medicine market, a sector that’s expected to generate $196.87 billion in revenues by 2025, according to a report by Grand View Research, Inc. (http://cnw.fm/vkGK0). The market has been driven by the popularity of herbal dietary supplements and other wellness therapies like yoga and acupuncture, but the recent global clamor for…

Continue Reading

ThursdayJun 21, 2018 11:38 am

CannabisNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) to Serve Domesticated Animals via CBD-based Suite of Products

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) has a suite of CBD-based pet products in development, targeting indications such as inflammation, post-surgical pain and joint pain, as well as skin disorders. An article discussing the company reads: “Pivot recently announced that it was accelerating development of its CBD pet product line, which will be marketed under the name ‘Pivot Naturals For Pets’ (http://cnw.fm/hSV8h). This product line will include capsules and sachets to deliver bio-available CBD, using Pivot’s proprietary and patented Ready-To-Infuse-Cannabis powder. In addition, the company is using its Thrudermic Transdermal Nanotechnology to develop and commercialize a series…

Continue Reading

WednesdayJun 20, 2018 1:40 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Continues to Develop Potential Uses of Patented Technology

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed and is already licensing DehydraTECH™, a technology that improves the bio-absorption and bioavailability of ingestible substances. A recent article discussing the company’s unique technology reads: “Application of the technology extends beyond nicotine to non-psychoactive cannabinoids, vitamins and non-steroidal anti-inflammatory drugs (NSAIDs), and Lexaria has licensed the technology to a number of companies, including chocolate maker Nuka Enterprises; cannabis beverage manufacturer GP Holdings; and Biolog, which markets hemp-based, cannabidiol (CBD)-infused products and vitamins. Lexaria is expected to sign 6-12 more licensing agreements in 2018. These are typically six-figure contracts in the first…

Continue Reading